188 related articles for article (PubMed ID: 22056872)
1. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.
Vesuna F; Lisok A; Kimble B; Domek J; Kato Y; van der Groep P; Artemov D; Kowalski J; Carraway H; van Diest P; Raman V
Oncogene; 2012 Jul; 31(27):3223-34. PubMed ID: 22056872
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.
Stone A; Valdés-Mora F; Gee JM; Farrow L; McClelland RA; Fiegl H; Dutkowski C; McCloy RA; Sutherland RL; Musgrove EA; Nicholson RI
PLoS One; 2012; 7(7):e40466. PubMed ID: 22808167
[TBL] [Abstract][Full Text] [Related]
3. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
Antoon JW; Martin EC; Lai R; Salvo VA; Tang Y; Nitzchke AM; Elliott S; Nam SY; Xiong W; Rhodes LV; Collins-Burow B; David O; Wang G; Shan B; Beckman BS; Nephew KP; Burow ME
PLoS One; 2013; 8(8):e69291. PubMed ID: 23950888
[TBL] [Abstract][Full Text] [Related]
4. PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α-Positive Breast Cancer Cells.
Gadad SS; Camacho CV; Malladi V; Hutti CR; Nagari A; Kraus WL
Mol Cancer Res; 2021 Oct; 19(10):1688-1698. PubMed ID: 34158394
[TBL] [Abstract][Full Text] [Related]
5. Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36.
Shen Y; Zhong J; Liu J; Liu K; Zhao J; Xu T; Zeng T; Li Z; Chen Y; Ding W; Wen G; Zu X; Cao R
Oncol Rep; 2018 Jun; 39(6):2604-2612. PubMed ID: 29620287
[TBL] [Abstract][Full Text] [Related]
6. CCAAT-displacement protein/cut homeobox transcription factor (CUX1) represses estrogen receptor-alpha (ER-α) in triple-negative breast cancer cells and can be antagonized by muscadine grape skin extract (MSKE).
Burton LJ; Hawsawi O; Sweeney J; Bowen N; Hudson T; Odero-Marah V
PLoS One; 2019; 14(4):e0214844. PubMed ID: 30964885
[TBL] [Abstract][Full Text] [Related]
7. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
Law EK; Sieuwerts AM; LaPara K; Leonard B; Starrett GJ; Molan AM; Temiz NA; Vogel RI; Meijer-van Gelder ME; Sweep FC; Span PN; Foekens JA; Martens JW; Yee D; Harris RS
Sci Adv; 2016 Oct; 2(10):e1601737. PubMed ID: 27730215
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic biomarker screening by FLIM-FRET for combination therapy in ER+ breast cancer.
Liu W; Cui Y; Ren W; Irudayaraj J
Clin Epigenetics; 2019 Jan; 11(1):16. PubMed ID: 30700309
[TBL] [Abstract][Full Text] [Related]
9. New insights into estrogenic regulation of
Paranjpe A; Bailey NI; Konduri S; Bobustuc GC; Ali-Osman F; Yusuf MA; Punganuru SR; Madala HR; Basak D; Mostofa A; Srivenugopal KS
J Biomed Res; 2016 Sep; 30(5):393-410. PubMed ID: 27845303
[TBL] [Abstract][Full Text] [Related]
10. A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg KA; Viswanadhapalli S; Mann M; Chakravarty D; Krishnan S; Liu Z; Liu J; Pratap UP; Ebrahimi B; Sanchez JR; Li X; Ma S; Park BH; Santhamma B; Chen Y; Lai Z; Raj GV; Yuan Y; Zhou D; Sareddy GR; Tekmal RR; McHardy S; Huang TH; Rao MK; Vankayalapati H; Vadlamudi RK
Cancer Res; 2022 Oct; 82(20):3830-3844. PubMed ID: 35950923
[TBL] [Abstract][Full Text] [Related]
11. BETs abet Tam-R in ER-positive breast cancer.
Alluri PG; Asangani IA; Chinnaiyan AM
Cell Res; 2014 Aug; 24(8):899-900. PubMed ID: 25001387
[TBL] [Abstract][Full Text] [Related]
12. Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies.
Fletcher KA; Alkurashi MH; Lindsay AJ
Breast Cancer Res Treat; 2024 Apr; 204(3):631-642. PubMed ID: 38228924
[TBL] [Abstract][Full Text] [Related]
13. NEAT1 repression by MED12 creates chemosensitivity in p53 wild-type breast cancer cells.
Zhang S; Kim EJ; Huang J; Liu P; Donahue K; Wang Q; Wang Y; Mcilwain S; Xie L; Chen X; Li L; Xu W
FEBS J; 2024 May; 291(9):1909-1924. PubMed ID: 38380720
[TBL] [Abstract][Full Text] [Related]
14. Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
Blawski R; Vokshi BH; Guo X; Kittane S; Sallaku M; Chen W; Gjyzari M; Cheung T; Zhang Y; Simpkins C; Zhou W; Kulick A; Zhao P; Wei M; Shivashankar P; Prioleau T; Razavi P; Koche R; Rebecca VW; de Stanchina E; Castel P; Chan HM; Scaltriti M; Cocco E; Ji H; Luo M; Toska E
Cell Rep; 2024 May; 43(5):114174. PubMed ID: 38700982
[TBL] [Abstract][Full Text] [Related]
15. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
Perez-Plasencia C; Duenas-Gonzalez A
Mol Cancer; 2006 Jul; 5():27. PubMed ID: 16831224
[TBL] [Abstract][Full Text] [Related]
16. Estrogen and tamoxifen up-regulate FXYD3 on breast cancer cells: assessing the differential roles of ER α and ZEB1.
Herrmann P; Aronica SM
Springerplus; 2015; 4():245. PubMed ID: 26090296
[TBL] [Abstract][Full Text] [Related]
17. SIRT1 mediates breast cancer development and tumorigenesis controlled by estrogen-related receptor β.
Parija M; Prakash S; Krishna BM; Dash S; Mishra SK
Breast Cancer; 2024 May; 31(3):440-455. PubMed ID: 38421553
[TBL] [Abstract][Full Text] [Related]
18. Enhanced ZnR/GPR39 Activity in Breast Cancer, an Alternative Trigger of Signaling Leading to Cell Growth.
Ventura-Bixenshpaner H; Asraf H; Chakraborty M; Elkabets M; Sekler I; Taylor KM; Hershfinkel M
Sci Rep; 2018 May; 8(1):8119. PubMed ID: 29802348
[TBL] [Abstract][Full Text] [Related]
19. The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.
Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia KM; Du Q; Laven-Law G; Nair SS; Yong A; Wilkinson A; Clifton S; Milioli HH; Alexandrou S; Caldon CE; Song J; Khoury A; Meyer B; Chen W; Pidsley R; Qu W; Gee JMW; Schmitt A; Wong ES; Hickey TE; Lim E; Clark SJ
Nat Struct Mol Biol; 2024 Mar; 31(3):498-512. PubMed ID: 38182927
[TBL] [Abstract][Full Text] [Related]
20. The Role of ERα36 in Development and Tumor Malignancy.
Thiebaut C; Konan HP; Guerquin MJ; Chesnel A; Livera G; Le Romancer M; Dumond H
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32526980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
